Which of the following is not used in the treatment of pulmonary hypeension?
**Core Concept**
Pulmonary hypertension (PH) is a progressive and potentially fatal condition characterized by elevated pulmonary artery pressure, leading to right heart failure. Treatment aims to reduce symptoms, improve quality of life, and delay disease progression.
**Why the Correct Answer is Right**
The treatment of pulmonary hypertension involves a multidisciplinary approach, including pharmacological, interventional, and surgical modalities. Commonly used agents include endothelin receptor antagonists (ERAs), such as bosentan, ambrisentan, and macitentan, which block the vasoconstrictive effects of endothelin-1. Phosphodiesterase-5 inhibitors (PDE-5Is), like sildenafil and tadalafil, enhance nitric oxide-mediated vasodilation. Prostacyclins, including epoprostenol, treprostinil, and iloprost, are used to reduce pulmonary vascular resistance. However, **Option A: Calcium channel blockers (CCBs)** are not used as a monotherapy in the treatment of pulmonary hypertension. CCBs may be used in specific cases, such as in patients with idiopathic PAH and a positive vasodilator response during right heart catheterization, but they are not a standard treatment option.
**Why Each Wrong Option is Incorrect**
**Option B:** ERAs, PDE-5Is, and prostacyclins are all used in the treatment of pulmonary hypertension. They are considered first-line therapies for various forms of the disease.
**Option C:** Prostacyclins are used in the treatment of pulmonary hypertension, particularly in patients with advanced disease or those who have failed other therapies.
**Clinical Pearl / High-Yield Fact**
When managing pulmonary hypertension, it's crucial to consider the underlying etiology, as this will guide treatment choices. For example, patients with pulmonary arterial hypertension may respond to ERAs or PDE-5Is, while those with pulmonary hypertension due to left heart disease may require different therapeutic strategies.
**Correct Answer: A. Calcium channel blockers (CCBs) are not used as a monotherapy in the treatment of pulmonary hypertension.